Online First

Case Report
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia
E. Tamellini1, M. Sorio2, A. Andreini2, C. Tecchio1,2, G. Nadali2, A. Bernardelli2, I. Ferrarini1,2, L. Crosera1,2, A. Vatteroni1,2, C. Simio1,2, F. Benedetti2, M. Krampera1,2, I. Tanasi2

1Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy

2Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

acute myeloid leukemia, post-transplant relapse, FLT3-inhibitors
Submitted:January 27, 2024
Accepted:February 27, 2024
Published online:June 14, 2024


Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.



Online ISSN:2432-7026